发明公开
- 专利标题： Medicaments for increasing endogenous erythropoietine (EPO)
- 专利标题（中）： 药品增加内源性促红细胞生成素（EPO）
-
申请号： EP10181768.2申请日： 2002-12-06
-
公开(公告)号： EP2289531A3公开(公告)日： 2013-03-13
- 发明人: Klaus, Stephen J. , Lin, Al Y. , Neff, Thomas B. , Wang, Qingjian , Guenzler-Pukall, Volkmar , Arend, Michael P. , Flippin, Lee A.
- 申请人： Fibrogen, Inc.
- 申请人地址： 409 Illinois Street San Francisco, CA 94158 US
- 专利权人： Fibrogen, Inc.
- 当前专利权人： Fibrogen, Inc.
- 当前专利权人地址： 409 Illinois Street San Francisco, CA 94158 US
- 代理机构： Goodfellow, Hugh Robin
- 优先权： US337082P 20011206; US349659P 20020116; US359683P 20020225; US386488P 20020605
- 主分类号： A61K38/00
- IPC分类号： A61K38/00 ; C12N15/09 ; C12Q1/56 ; C12Q1/34 ; A61K31/00 ; A61K31/47 ; A61K31/4738 ; A61K31/63 ; A61P7/06 ; A61K38/17 ; C07K14/47 ; C07K14/505 ; G01N33/74
摘要：
The present invention relates to compounds for use in methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo . Compounds for use in methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included.
公开/授权文献
- EP2289531B1 Medicaments for the treatment or prevention of anemia 公开/授权日：2018-07-04
信息查询
IPC分类:
